Enveric Biosciences, Inc. is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. Its lead candidate, EB-003, a novel DMT derivative, is designed to selectively engage 5-HT2A and 5-HT1B receptors to deliver antidepressant and anxiolytic effects without hallucinogenic properties. The company leverages a proprietary drug discovery platform and patent-protected chemical library (Psybrary) to advance non-hallucinogenic psychedelic-inspired compounds through preclinical and clinical development.
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001493152-26-013294 | EDGAR | 67K words |
| 2025-03-28 | 2024-12-31 | 0001641172-25-001296 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001493152-24-011210 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010431 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001493152-22-008510 | EDGAR | — |
| 2021-04-01 | 2020-12-31 | 0001493152-21-007757 | EDGAR | — |
| 2020-03-25 | 2019-12-31 | 0001140361-20-006825 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001140361-19-005573 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001140361-18-016275 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001079974-17-000125 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001493152-25-023540 | EDGAR | 18K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-024021 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001641172-25-010345 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045859 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001493152-24-031352 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019364 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040493 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001493152-23-027881 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001493152-23-016990 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001493152-22-032131 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001493152-22-022369 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001493152-22-013332 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001493152-26-013290 | EDGAR | 2K words |
| 2026-02-06 | 0001493152-26-005606 | EDGAR | — |
| 2026-01-28 | 0001493152-26-004055 | EDGAR | — |
| 2026-01-09 | 0001493152-26-001151 | EDGAR | — |
| 2025-12-12 | 0001493152-25-027541 | EDGAR | — |
| 2025-12-11 | 0001493152-25-027196 | EDGAR | — |
| 2025-11-14 | 0001493152-25-023444 | EDGAR | — |
| 2025-11-14 | 0001493152-25-023441 | EDGAR | — |
| 2025-10-23 | 0001493152-25-019095 | EDGAR | — |
| 2025-09-18 | 0001493152-25-014073 | EDGAR | — |
476 total filings indexed. 444 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000890821 |
| Ticker | ENVB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Cambridge, MA |
| Website | https://www.enveric.com |
| Listed | 1995-08-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ENVB (~200 tokens, structured JSON with cryptographic provenance)